Eugenol Inclusion In Oral Pain Monograph Requires Actual Use Data – FDA
This article was originally published in The Tan Sheet
Executive Summary
Both a clinical safety trial and an actual use study are necessary to support including eugenol in the oral discomfort (relief) products final monograph, FDA tells the Consumer Healthcare Products Association
You may also be interested in...
CHPA Benzocaine Study Protocol Includes Consumer Research Survey
Studying OTC toothache relief ingredient benzocaine in an actual use setting presents "insurmountable hurdles," the Consumer Healthcare Products Association tells FDA in an April 16 briefing document
Benzocaine studies
CHPA's Oral Discomfort Task Group requests FDA meeting by end of April to "facilitate development of a mutually agreeable approach to studying clinically the benefits and use patterns of benzocaine," trade association says in March 22 letter to agency. CHPA will provide FDA with a background document two weeks before meeting containing rationale for the proposed study designs, responses to agency concerns about protocol. CHPA request responds to FDA's Jan. 8 letter, in which agency questioned proposed protocol for testing efficacy of benzocaine and eugenol for toothache relief (1"The Tan Sheet" Jan. 21, 2002, p. 5). Eugenol-related issues "will be addressed separately," CHPA says...
CHPA Benzocaine Toothache Relief Efficacy Study Protocol Submitted To FDA
Individuals with either moderate or severe toothache pain are included in a study protocol on the effectiveness of benzocaine for toothache relief submitted to FDA by the Consumer Healthcare Products Association Oral Discomfort Task Group.